Bruton tyrosine kinase (BTK) and its role in B-cell malignancy

International Reviews of Immunology

Volumn 31, Issue 2, 2012, Pages 119-132

  Buggy, Joseph J ^a   Elias, Laurence ^a  

^a PHARMACYCLICS INC   (United States)

Author keywords

B cell receptor; Kinase; Leukemia; Lymphoma; PCI 32765; X linked agammaglobulinemia

Indexed keywords

2 CYANO N (2,5 DIBROMOPHENYL) 3 HYDROXYCROTONAMIDE; AVL 292; B LYMPHOCYTE ANTIGEN; BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE INHIBITOR; CHEMOKINE; DASATINIB; IBRUTINIB; LYMPHOCYTE ANTIGEN RECEPTOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER CELL; CELL INTERACTION; CELL LINEAGE; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; IC 50; INNATE IMMUNITY; LARGE CELL LYMPHOMA; LEUKEMIA; LYMPHOCYTE FUNCTION; LYMPHOID CELL; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ANIMALS; B-LYMPHOCYTES; HUMANS; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; MICE; PROTEIN-TYROSINE KINASES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 84860433198     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2012.664797     Document Type: Review

References (130)

1. Bruton, O.C. (1952) Agammaglobulinemia. Pediatrics: 9;722-8.
2. Vetrie D, Vorechovský I, Sideras P, et al.The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361:226-233. (Pubitemid 23034471)
3. Tsukada S, Saffran DC, Rawlings DJ et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993;72:279-290. (Pubitemid 23044942)
4. Genevier HC, Hinshelwood S, Gaspar HB, et al. Expression of Bruton's tyrosine kinase protein within the B cell lineage. Eur J Immunol. 1994;24:3100-3105.
5. Smith CI, Baskin B, Humire-Greiff P, et al. Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol. 1994;152:557-565. (Pubitemid 24072959)
6. de Weers M, Verschuren MCM, Kraakman MEM, et al. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up tomature B cell stages. Eur J.Immunol. 1993;23:3109-3114. (Pubitemid 23353756)
7. Conley ME, Dobbs AK, Farmer DM et al. Primary B cell immunodeficiencies: comparisons and contrasts. Annu. Rev. Immunol. 2009;27:199-227.
8. Tsukada S, Rawlings DJ, Witte ON Role of Bruton's tyrosine kinase in immunodeficiency. Curr. Opin. Immunol. 1994;6:623-630. (Pubitemid 24249522)
9. Rawlings DJ, Saffran DC, Tsukada S, et al.Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XIDmice. Science 1993;261:358-361. (Pubitemid 23281007)
10. Satterthwaite AB, Cheroutre H, Khan WN, Sideras P, Witte ON. Btk dosage determines sensitivity to B cell antigen receptor cross-linking. Proc Natl. Acad. Sci. U. S. A. 1997;94:13152-13157.
11. Kerner, JD, ApplebyMW,Mohr RN, et al. Impaired expansion ofmouse B cell progenitors lacking Btk. Immunity. 1995;3:301-312.
12. Mohamed AJ,Nore BF, Christensson B, Smith CIE. Signaling of Bruton's tyrosine kinase, Btk. 1999; Scand J. Immunol 49:113-118. (Pubitemid 29096305)
13. Li T, Rawlings DJ, Park H, et al. Constitutivemembrane association potentiates activation of Bruton tyrosine kinase. Oncogene 1997;15:1357-1383.
14. Varnai P, Rother KI, and Balla T. Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton's tyrosine kinase pleckstrin homology domain visualized in single living cells. J. Biol. Chem. 1999;274:10983-10989.
15. Humphries LA, Dangelmaier C, Sommer K et al. Tec kinasesmediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase C gamma Src homology 2-Src homology 3 linker. J Biol Chem. 2004;279:37651-37661. (Pubitemid 39195478)
16. Fluckiger AC, Li Z, Kato RM, et al. Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation. EMBO J. 1998;17:1973-1985. (Pubitemid 28154527)
17. Jiang A, Craxton A, Kurosaki T, Clark EA. Different protein tyrosine kinases are required for B cell antigen receptor-mediated activation of extracellular signal-regulated kinase, c-JunNH2-terminal kinase 1, and p38 mitogen-activated protein kinase. J. ExpMed. 1998;188:1297-1306. (Pubitemid 28478018)
18. Kurosaki T. Genetic analysis of B cell antigen receptor signaling. Annu Rev. Immunol. 1999;17:555-592. (Pubitemid 29241134)
19. Mao C, ZhouM, Uckun FM. Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia. J. Biol Chem. 2001;276:41435-41443.
20. Marcotte DJ, Liu YT, Arduini RM, et al. Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Protein. Sci. 2010;19:429-439.
21. Kuglstatter A,Wong A, Tsing S, et al. Insights into the conformational flexibility of Bruton's tyrosine kinase frommultiple ligand complex structures. Protein Sci. 2011;20:428-436.
22. Niiro H, Clark EA Regulation of B-cell fate by antigen-receptor signals. Nat. Rev. Immunol. 2002;2:945-956. (Pubitemid 37323215)
23. Kraus, M., Alimzhanov, M. B., Rajewsky, N, Rajewsky, K. Survival of restingmature B lymphocytes depends on BCR signaling via the Igα/β heterodimer. Cell 2004;117:787-800. (Pubitemid 38748894)
24. Lam KP, Kuhn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997;90:1073-1083. (Pubitemid 27408521)
25. Gauld SB, Dal Porto JM, Cambier JC B cell antigen receptor signaling: roles in cell development and disease. Science 2002;296:1641-1642. (Pubitemid 34579149)
26. Afar DE, Park H, Howell BWet al. Regulation of Btk by Src family tyrosine kinases.Mol. Cell. Biol. 1996;16:3465-3471. (Pubitemid 26199865)
27. Cheng G, Ye ZS, Baltimore D. Binding of Bruton's tyrosine kinase to Fyn, Lyn, orHck through a Src homology 3 domain-mediated interaction. Proc Natl. Acad. Sci. USA. 1994;91:8152-8155. (Pubitemid 24253904)
28. Pereira S, Lowell C. (2003)TheLyn tyrosine kinase negatively regulates neutrophil integrin signaling. J Immunol. Aug 1;171(3):1319-27. (Pubitemid 36900063)
29. Kawakami Y, Kitaura J, Satterthwaite AB, et al. Redundant and opposing functions of two tyrosine kinases, Btk and Lyn, inmast cell activation. J Immunol. 2000;165:1210-9. (Pubitemid 30604546)
30. Srinivasan L, Sasaki Y, Calado DP, et al. PI3 kinase signals BCR-dependentmature B cell survival. Cell. 2009;139:573-586.
31. Anderson JS, Teutsch M, Dong Z, Wortis HH. An essential role for Bruton's tyrosine kinase in the regulation of B-cell apoptosis. Proc. Natl. Acad. Sci USA. 1996;93:10966-10971.
32. Petro, JB, Rahman SM, Ballard DW, Khan WN. Bruton's tyrosine kinase is required for activation of IkB kinase and nuclear factor kB in response to B cell receptor engagement. J. Exp. Med. 2000;191:1745-1754.
33. Saijo K, Mecklenbrauker I, Santana A, et al. Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha. J. Exp. Med 2002;195:1647-1652. (Pubitemid 34666078)
34. Khan WN. Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase. Immunol Res. 2001;23:147-56. (Pubitemid 32575356)
35. Yu L,Mohamed AJ, Simonson OE, et al. Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB. Blood. 2008;111:4617-26.
36. Jongstra-Bilen J, Puig Cano A,Hasija M, Xiao H, Smith CI, Cybulsky MI:Dual functions of Bruton's tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis. J. Immunol. 2008;181:288-298.
37. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Immunol. 2008;8:34-47.
38. Chang BY,HuangMM,FrancescoM, et al.TheBruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition ofmultiple effector cells. Arthritis ResTher. 2011;13:R115
39. Ortolano S, Hwang IY, Han SB, Kehrl JH. Roles for phosphoinositide 3-kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing. Eur J Immunol. 2006;36:1285-1295.
40. de Gorter DJ, Beuling EA, Kersseboom R, et al. Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity. 2007;26:93-104. (Pubitemid 46109347)
41. Bajenoff M, Egen JG, Koo LY, et al. Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. Immunity. 2006;25:989-1001. (Pubitemid 44914055)
42. Kinashi T. Intracellular signaling controlling integrin activation in lymphocytes. Nature Rev Immunol. 2005;5:546-559. (Pubitemid 40961332)
43. Jiang Y,MaW,Wan Y, Kozasa T,Hattori S,Huang XY.TheG protein G alpha12 stimulates Bruton's tyrosine kinase and a rasGAP through a conserved PH/BMdomain. Nature 1998;395:808-13. (Pubitemid 28485449)
44. Lowry WE, Huang XY. G Protein beta gamma subunits act on the catalytic domain to stimulate Bruton's agammaglobulinemia tyrosine kinase. J Biol Chem. 2002;277:1488-92. (Pubitemid 34968904)
45. Spaargaren M, Beuling EA, Rurup ML, et al.The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J ExpMed. 2003;198:1539-1550. (Pubitemid 37467168)
46. Sochorová K, Horváth R, Rozková D, Litzman J, Bartunková J. Impaired Toll-like receptor 8- mediated IL-6 and TNF-alpha production in antigen-presenting cells from patients with X-linked agammaglobulinemia. Blood. 2007;109:2553-6. (Pubitemid 46425901)
47. Horwood NJ, Mahon T, McDaid JP, et al. Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor alpha production. J Exp Med. 2003;197:1603-1611. (Pubitemid 36745336)
48. Liu X, Zhan Z, Li D, et al. IntracellularMHC class II molecules promote TLR-triggered innate immune responses bymaintaining activation of the kinase Btk. Nat Immunol. 2011;12:416-424.
49. Lee K, Xu S, Wong E, Tergaonkar V, Lam, K. Bruton's tyrosine kinase separately regulates NFkB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B cells. J. Biol. Chem. 2008;283:11189-11198.
50. Hasan M, Lopez-Herrera G, Blomberg EM, et al. Defective Toll-like receptor 9-mediated cytokine production in B cells from Bruton's tyrosine kinase-deficient mice. Immunology 2007;123:239-249.
51. Jahrsdorfer B, Muhlenhoff L, Blackwell SE, et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res. 2005;11:1490-1499. (Pubitemid 40315231)
52. Decker T, Schneller F, Sparwasser T, et al.ImmunostimulatoryCpG- oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000;95:999-1006. (Pubitemid 30062724)
53. James RG, Biechele TL, ConradWH et al. Bruton's tyrosine kinase revealed as a negative regulator of Wnt-beta-catenin signaling. Sci Signal 2009;2(72):ra25.
54. Kawakami Y, Miura T, Bissonnette R, et al. Bruton's tyrosine kinase regulates apoptosis and JNK/SAPK kinase activity. Proc Natl Acad Sci U S A. 1997;94:3938-42.
55. Matsuda T, Takahashi-Tezuka M, Fukada T, et al. Association and activation of Btk and Tec tyrosine kinases by gp130, a signal transducer of the interleukin-6 family of cytokines. Blood 1995;85:627-33.
56. Rajaiya J, Hatfield M, Nixon JC, Rawlings DJ, Webb CF. Bruton's tyrosine kinase regulates immunoglobulin promoter activation in association with the transcription factor Bright. Mol Cell Biol. 2005;25:2073-84. (Pubitemid 40354608)
57. Mukhopadhyay S,Mohanty M,Mangla A, et al.Macrophage effector functions controlled by Bruton's tyrosine kinase are more crucial than the cytokine balance of T cell responses for microfilarial clearance. J. Immunol. 2002;168:2914-2921. (Pubitemid 34211671)
58. Mueller H, Stadtmann A, Van Aken H, et al. Tyrosine kinase Btk regulates E-selectin-mediated integrin activation and neutrophil recruitment by controlling phopholipase C (PLC) γ2 and PI3Kγ pathways. Blood 2010;115:3118-3127.
59. Fiedler K, Sindrilaru A, Terszowski G, et al. Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia. Blood 2011;117:1329-1339.
60. Su Q, Zhou Y, Johns RA. Bruton's tyrosine kinase (Btk) is a binding partner for hypoxia inducedmitogenic factor (HIMF/FIZZ1) and mediatesmyeloid cell chemotaxis. FASEB J. 2007;21:1376-1382. (Pubitemid 46684840)
61. Mangla A, Khare A, Vineeth V et al. Pleiotropic consequences of Bruton tyrosine kinase deficiency inmyeloid lineages lead to poor inflammatory responses. Blood 2004;104:1191-1197. (Pubitemid 39038042)
62. Lee SH, Kim T, Jeong D, Kim N, Choi Y. The tec family tyrosine kinase Btk Regulates RANKLinduced osteoclastmaturation. J Biol Chem. 2008;283:11526-11534.
63. ShinoharaM, Koga T, Okamoto K, et al. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell 2008;132:794-806. (Pubitemid 351312796)
64. Danks L,Workman S,WebsterD,Horwood NJ. Elevated cytokine production restores bone resorption by human Btk-deficient osteoclasts. J BoneMiner Res 2011;26:182-192.
65. Gilfillan AM, Tkaczyk C. Integrated signalling pathways formast-cell activation.Nat Rev Immunol. 2006;6:218-30. (Pubitemid 43290991)
66. Kawakami Y, Yao L, Miura T, Tsukada S, Witte O, Kawakami T. Tyrosine phosphorylation and activation of Bruton tyrosine kinase upon Fc epsilon RI cross-linking. Mol Cell Biol. 1994;14:5108-5113. (Pubitemid 24235938)
67. Hata BD, Kawakami Y, Inagaki N, et al. Involvement of Bruton's tyrosine kinase in FcεRIdependentmast cell degranulation and cytokine production. J ExpMed. 1998;187:1235-1247. (Pubitemid 28189113)
68. MacGlashan D Jr. IgE receptor and signal transduction inmast cells and basophils.Curr Opin Immunol. 2008;20:717-23.
69. Setoguchi R, Kinashi T, Sagara H, Hirosawa K, Takatsu K. Defective degranulation and calcium mobilization of bone-marrow derived mast cells from Xid and Btk-deficient mice. Immunol Lett. 1998;64:109-18. (Pubitemid 28553020)
70. Johansson A, Rudolfsson S, Hammarsten P, et al. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. AmJ Pathol. 2010;177:1031-41.
71. Soucek L, Buggy JJ, Kortlever R, et al.Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma. Neoplasia. 2011;13:1093-100.
72. Liu J, Fitzgerald ME, Berndt MC, Jackson CW, Gartner TK. Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood 2006;108:2596-2603.
73. Oda A, Ikeda Y, Ochs HD, et al. Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/ Tec kinases in platelets induced by collagen binding of CD32 cross-linking. 2000; Blood 95:1663-1670. (Pubitemid 30120827)
74. Quek LS, Bolen J,Watson SP. A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol. 1998;8:1137-1140. (Pubitemid 28501379)
75. van derMeer JW,Weening RS, Schellekens PT, vanMunster IP, Nagengast FM. Colorectal cancer in patients with X-linked agammaglobulinaemia. Lancet 1993;341:1439-1440. (Pubitemid 23161446)
76. Brosens LA, Tytgat KM, Morsink FH, et al. Multiple colorectal neoplasms in X-linked agammaglobulinemia. Clin. Gastroenterol. Hepatol. 2008;6:115-119. (Pubitemid 350309526)
77. Middendorp S, Zijlstra AJ, Kersseboom R, Dingjan GM, Jumaa H, Hendriks RW. Tumor suppressor function of Bruton tyrosine kinase is independent of its catalytic activity. Blood. 2005;105:259-65. (Pubitemid 40053091)
78. Mohamed AJ, Yu L, Bäckesjö CM, et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009;228:58-73.
79. Meeker T, Lowder J, Cleary ML, et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl JMed. 1985;312:1658-1665. (Pubitemid 15068572)
80. Kuppers R.Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5:251-262. (Pubitemid 40488631)
81. GururajanM, Jennings CD, Bondada S. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J. Immunol. 2006;176:5715-5719.
82. Irish JM, Czerwinski DK, Nolan GP, Levy R. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood 2006;108:3135-3142.
83. Lopez-Giral S, Quintana NE, Cabrerizo M, et al. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol. 2004;76:462-471. (Pubitemid 39006961)
84. Pals ST, de Gorter DJJ, Spaargaren M. Lymphoma dissemination: the other face of lymphocyte homing. Blood 2007;110:3102-3111. (Pubitemid 350106300)
85. Teicher BA, Fricker SP. CXCL12(SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16:2927-2931.
86. Kurtova AV, Tamayo AT, Ford RD, Burger JA Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 2009;113:4604-4613.
87. Trentin L, Cabrelle A, Facco M, et al.Homeostatic chemokines drivemigration ofmalignant B cells in patients with non-Hodgkin lymphomas. Blood. 2004;104:502-508. (Pubitemid 38900034)
88. Kurtova AV, Tamayo AT, Ford RJ, Burger JA. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 2009;113:4604-4613.
89. QuirogaMP, Balakrishnan K, Kurtova AV, et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009;114:1029-1037.
90. Burger JA, Quiroga MP, Hartmann E, et al. High-level expression of the T cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood. 2009;113:3050-3058.
91. Sanz-Rodriguez F, Hidalgo A, Teixido J. Chemokine stromal cell-derived factor-1 alpha modulates VLA-4 integrin-mediatedmultiplemyeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood. 2001;97:346-351. (Pubitemid 32060316)
92. Corcione A, Arduino N, Ferretti E, et al. CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells. Clin Cancer Res; 2004: 10:964-971. (Pubitemid 38198897)
93. Lenz G, Wright G, Dave SS et al. Stromal gene signatures in large-B-cell lymphomas.NEngl JMed. 2008;359:2313-2323.
94. Petit I, Jin D, Rafii S The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neoangiogenesis. Trends Immunol. 2007;28:299-307. (Pubitemid 46963141)
95. Mahajan S, Ghosh S, Sudbeck EA, et al. Rational design and synthesis of a novel antileukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxybeta- methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem. 1999;274:9587-99.
96. van den Akker E, van Dijk TB, Schmidt U, et al.The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity. Biol Chem 2004;385:409-13. (Pubitemid 38787119)
97. Uckun FM Chemosensitizing anti-cancer activity of LFM-A13, a leflunomide metabolite analog targeting polo-like kinases. Cell Cycle 2007:6;3021-6.
98. Hantschel O, Rix U, Schmidt U, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A. 2007; 104;13283-8. (Pubitemid 47293937)
99. Honigberg L, Smith AM, Sirisawad M, et al.The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cellmalignancy. Proc Natl Acad Sci U S A. 2010;107:13075-80.
100. Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007;2:58-61.
101. Advani RH, Sharman JP, Smith SM et al. The Btk Inhibitor PCI-32765 Is Highly Active And Well Tolerated In Patients (Pts) With Relapsed/Refractory B Cell Malignancies: Final Results From A Phase I Study Ann Oncol 2011;22 (suppl 4): 153
102. Evans, E, Tester, R, Aslanian S, et al. ClinicalDevelopment of AVL-292; A Potent, SelectiveCovalent Btk Inhibitor for the Treatment of B Cell Malignancies. ASH Annual Meeting Abstracts. 2011;118: 3485
103. MacGlashan D,Honigberg LA, SmithA,Buggy J, Schroeder JT Inhibition of IgE-mediated secretion fromhumanbasophilswith a highly selectiveBruton's tyrosine kinase,Btk, inhibitor. International Immunopharmacology 2011;11:475-479.
104. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signaling in diffuse large B-cell lymphoma. Nature 2010;463:88-92.
105. Sabine P, Balasubramanian, S, Pham, LV et al. Activity of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 inMantle Cell Lymphoma (MCL) Identifies Btk As a NovelTherapeutic Target ASH AnnualMeeting Abstracts, 2011;118:3688
106. Middendorp S, Dingjan GM,Maas A et al. Function of Bruton's Tyrosine Kinase during B Cell Development Is Partially Independent of Its Catalytic Activity J Immunol. 2003;171:5988-5996.
107. Chan AC, Iwashima M, Turck CW,Weiss A. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell. 1992;71:649-662.
108. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101:4944-4951. (Pubitemid 36857758)
109. Chen L. Apgar J, Huynh L, et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia Blood. 2005;105:2036-2041.
110. Chiorazzi N, FerrariniM.Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities Blood 2011;117:1781-91.
111. Corcos D, OsbornMJ,Matheson LS. B-cell receptors and heavy chain diseases: guilty by associationč Blood. 2011;117:6991-8.
112. O'Brien S,Burger JA,BlumKet al.TheBruton's TyrosineKinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study ASH AnnualMeeting Abstracts. 2011;118:983
113. Chang, BY, Francesco, M,Magadala, et al. Egress of CD19+CD5+Cells Into Peripheral Blood Following Treatmentwith the Bruton TyrosineKinase Inhibitor, PCI-32765, inMantle Cell Lymphoma Patients ASH AnnualMeeting Abstracts. 2011, 118:954
114. Herman SE, Gordon AL,Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117:6287-6296.
115. Ponader S, Chen SS, Buggy JJ, et al. Bruton's tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. Dec 16, 2011. [Epub ahead of print]
116. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511. (Pubitemid 30082188)
117. Staudt, LM, Dunleavy K, Buggy JJ, et al. The Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 Modulates Chronic Active BCR Signaling and Induces Tumor Regression in Relapsed/Refractory ABC DLBCL ASH AnnualMeeting Abstracts. 2011;118:2716
118. Wang, L, Martin, P, Blum, KA, et al. The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-TreatedMantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. ASH AnnualMeeting Abstracts. 2011;118:442
119. Pighi C, Gu TL, Dalai I, et al. Phospho-proteomic analysis ofmantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. Cell Oncol (Dordr). 2011;34:141-53.
120. Psyrri A, Papageorgiou S, Liakata E, et al. Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res. 2009;15:5724-32.
121. Chauhan D, Li G, Auclair D, et al. Identification of genes regulated by dexamethasone inmultiple myeloma cells using oligonucleotide arrays. Oncogene 2002;21:1346-1358. (Pubitemid 34214500)
122. Tai, Y-T, Chang, BY, Kong, S-Y, et al. Targeting Brouton's Tyrosine Kinase with PCI-32765 Blocks Growth and Survival of Multiple Myeloma and Waldenström Macroglobulinemia Via Potent Inhibition of Osteoclastogenesis, Cytokines/Chemokine Secretion, andMyeloma Stem-Like Cells in the BoneMarrowMicroenvironment ASH AnnualMeeting Abstracts. 2011;118:883
123. Bam R, Pennisi A, Li X, et al. Bruton's Tyrosine Kinase (Btk) Is Indispensable for Myeloma Cell Migration towards SDF-1 and Induction of Osteoclastogenesis and Osteolytic Bone Disease. ASH AnnualMeeting Abstracts 2010;116:447.
124. Matsui W, Huff CA, Wang O, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004;103:2332-2336. (Pubitemid 38326254)
125. BamR, LingW, Khan S, et al. Cell Surface CXCR4 and BTK Expression Are Associated inMyeloma Cells and Osteoclast Precursors and Mediate Myeloma Cell Homing and Clonogenicity, and Osteoclastogenesis ASH AnnualMeeting Abstracts. 2011;118:884
126. FeldhahnN,Río P, SohBN, et al.Deficiency of Bruton's tyrosine kinase inBcellprecursor leukemia cells. Proc Natl Acad Sci U S A. 2005;102:13266-71. (Pubitemid 41325012)
127. Feldhahn N,Klein F,Mooster JL, et al.Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells J ExpMed. 2005;201:1837-52.
128. Jongstra-Bilen J, Puig Cano A, Hasija M, Xiao H, Smith CI, Cybulsky MI: Dual functions of Bruton's tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis. J Immunol 2008, 181:288-298.
129. Nimmerjahn F, Ravetch JV (2008). Fcγ receptors as regulators of immune responses.Nat Immunol 8:34-47.
130. SochorováK, Horváth R, RozkováD, Litzman J, Bartunková J (2007). Impaired Toll-like receptor 8- mediated IL-6 and TNF-alpha production in antigen-presenting cells from patients with X-linked agammaglobulinemia. Blood 109:2553-6. (Pubitemid 46425901)